Ticker >

Genomic Valley share price

Genomic Valley Biotech Ltd.

BSE: 539206 SECTOR: Agriculture  7521   10   0

35.90
+1.63 (4.76%)
BSE: 23 Feb 04:01 PM

Price Summary

Today's High

₹ 36

Today's Low

₹ 34.2

52 Week High

₹ 50.14

52 Week Low

₹ 20.65

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

10.97 Cr.

Enterprise Value

10.92 Cr.

No. of Shares

0.31 Cr.

P/E

10.41

P/B

3.05

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  11.78

CASH

0.04 Cr.

DEBT

0 Cr.

Promoter Holding

65.04 %

EPS (TTM)

₹  3.45

Sales Growth

3758.23%

ROE

20.24 %

ROCE

20.35%

Profit Growth

7040.47 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year3758.23%
3 Year47.61%
5 Year35.57%

Profit Growth

1 Year7040.47%
3 Year31.36%
5 Year80.23%

ROE%

1 Year20.24%
3 Year2.75%
5 Year3.82%

ROCE %

1 Year20.35%
3 Year5.38%
5 Year5.27%

Debt/Equity

0

Price to Cash Flow

-14.08

Interest Cover Ratio

225.302371404867

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 65.04 0
Sep 2023 66.32 0
Jun 2023 67.18 0
Mar 2023 67.18 0
Dec 2022 67.85 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 47.6053859763109% for the Past 3 years.
  • Company is virtually debt free.
  • Company’s PEG ratio is 0.00147910600018447.
  • Company has a healthy liquidity position with current ratio of 2.88501919634181.
  • The company has a high promoter holding of 65.04%.

 Limitations

  • Company has a poor ROE of 2.75354146314818% over the past 3 years.
  • Company has high debtor days of 297.291263164738.
  • Company has negative cash flow from operations of -0.7786652.
  • The company has a low EBITDA margin of -92.0740643042361% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 0.67 1 0.06 0.07 0.04
Total Expenditure 0.64 0.06 0.03 0.04 0.02
Operating Profit 0.03 0.93 0.03 0.02 0.02
Other Income 0.01 0.01 0 0 0
Interest 0 0 0 0 0
Depreciation 0 -0.01 0 0 0
Exceptional Items -0.9 0.03 0 0 0
Profit Before Tax -0.85 0.98 0.03 0.02 0.02
Tax 0 0 0 0 0
Profit After Tax -0.85 0.98 0.03 0.02 0.02
Adjusted EPS (Rs) -2.8 3.21 0.09 0.08 0.08

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 0.99 0.85 0.21 0.07 2.72
Total Expenditure 0.57 0.29 0.34 0.45 1.84
Operating Profit 0.42 0.55 -0.14 -0.38 0.88
Other Income 0.01 0.01 0 0.08 0.04
Interest 0 0.18 0.18 0.04 0
Depreciation 0.19 0.18 0.19 0.08 0.01
Exceptional Items 0 0 0 0.42 -0.26
Profit Before Tax 0.23 0.21 -0.5 0 0.65
Tax 0 -0.08 0.06 0.01 0
Net Profit 0.23 0.29 -0.56 -0.01 0.65
Adjusted EPS (Rs.) 0.76 0.94 -1.83 -0.03 2.12

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 3.05 3.05 3.05 3.05 3.05
Total Reserves 1.71 1.99 1.43 -0.18 0.47
Borrowings 1.48 1.48 1.55 0 0
Other N/C liabilities 0.86 0.65 0.7 0.7 0
Current liabilities 0.07 0.77 0.87 0.21 0.89
Total Liabilities 7.18 7.94 7.61 3.8 4.42
Assets
Net Block 4.31 4.47 5.86 1.75 0
Capital WIP 0.49 0.49 0.49 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 2.08 2.58 1.1 0.91 1.84
Other N/C Assets 0 0 0 0 0
Current Assets 0.3 0.4 0.16 1.14 2.58
Total Assets 7.18 7.94 7.61 3.8 4.42
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 0.23 0.21 -0.5 -0.42 0.91
Adjustment 0.18 0.18 0.19 -0.26 -0.03
Changes in Assets & Liabilities -1.45 0.06 1.8 -1.45 -1.66
Tax Paid 0 0 0 0 0
Operating Cash Flow -1.04 0.44 1.48 -2.13 -0.78
Investing Cash Flow 0.37 -0.47 -1.58 3.67 1.52
Financing Cash Flow 0.73 0 0.07 -1.55 -0.7
Net Cash Flow 0.06 -0.04 -0.03 -0.01 0.04

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 67.85 67.18 67.18 66.32 65.04
ojaswini avantika 0.07 0.07 0.07 0.07 0.07
parul agrawal 9.29 9.29 9.29 9.29 9.29
yogesh agrawal 58.50 57.82 57.82 56.97 55.69
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 32.15 32.82 32.82 33.68 34.96
amar aggarwal 9.05 9.05 9.05 9.05 9.05
deepti aggarwal 11.00 11.00 11.00 11.00 11.00
harish chandra sharma 11.41 11.41 11.35 8.73 4.81

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Genomic Valley - Quaterly Results14 Feb 2024, 6:48PM Genomic Valley Biotech informs about certificate11 Jan 2024, 5:20PM Genomic Valley - Quaterly Results10 Feb 2023, 1:58PM Genomic Valley - Quaterly Results10 Feb 2023, 1:58PM Genomic Valley - Quaterly Results10 Feb 2023, 1:58PM Genomic Valley Biotech informs about appointment of company secretary 21 Dec 2022, 3:21PM Genomic Valley Biotech informs about newspaper publication8 Dec 2022, 2:57PM Genomic Valley Biotech informs about annual report7 Dec 2022, 3:55PM Genomic Valley Biotech informs about disclosure of related party transactions26 Nov 2022, 3:19PM Genomic Valley - Quaterly Results20 Jul 2022, 1:16PM Genomic Valley - Quaterly Results20 Jul 2022, 1:16PM Genomic Valley - Quaterly Results20 Jul 2022, 1:16PM Genomic Valley Biotech informs about disclosure13 May 2022, 4:53PM Genomic Valley - Quaterly Results12 Feb 2022, 3:18PM Genomic Valley Biotech informs about newspaper advertisements4 Feb 2022, 4:16PM Genomic Valley Biotech informs about certificate 11 Jan 2022, 2:53PM Genomic Valley Biotech informs about newspaper advertisements9 Dec 2021, 4:57PM Genomic Valley Biotech informs about AGM8 Dec 2021, 12:37PM Genomic Valley Biotech informs about book closure 7 Dec 2021, 4:06PM Genomic Valley Biotech informs about appointment of CS cum CO 6 Dec 2021, 2:02PM Genomic Valley Biotech informs about outcome of board meeting25 Nov 2021, 9:49AM Genomic Valley Biotech informs about trading window closure1 Nov 2021, 4:27PM Genomic Valley Biotech informs about board meeting1 Nov 2021, 4:19PM Genomic Valley Biotech informs about certificate14 Oct 2021, 3:47PM Genomic Valley Biotech informs about board meeting2 Aug 2021, 3:08PM Genomic Valley Biotech informs about resignation of CS cum CO10 Jun 2021, 12:25PM Genomic Valley Biotech informs about certificate16 Apr 2021, 12:18PM Genomic Valley Biotech informs about disclosure30 Nov 2020, 4:44PM

Genomic Valley Stock Price Analysis and Quick Research Report. Is Genomic Valley an attractive stock to invest in?

 

Stock investing requires careful analysis of financial data to find out the company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement. This can be time-consuming and cumbersome. An easier way to find out about a company's performance is to look at its financial ratios, which can help to make sense of the overwhelming amount of information that can be found in a company's financial statements.

Here are the few indispensable tools that should be a part of every investor’s research process.

  • PE ratio: - Price to Earnings' ratio, which indicates for every rupee of earnings how much an investor is willing to pay for a share. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Genomic Valley has a PE ratio of 10.4136450658467 which is low and comparatively undervalued .

  • Share Price: - The current share price of Genomic Valley is Rs 35.9. One can use valuation calculators of ticker to know if Genomic Valley share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Genomic Valley has ROA of 15.7775465238897 % which is a good sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Genomic Valley has a Current ratio of 2.88501919634181 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Genomic Valley has a ROE of 20.2405322611302 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Genomic Valley has a D/E ratio of 0 which means that the company has low proportion of debt in its capital.

  • Inventory turnover ratio: - Inventory Turnover ratio is an activity ratio and is a tool to evaluate the liquidity of a company's inventory. It measures how many times a company has sold and replaced its inventory during a certain period of time. Genomic Valley has an Inventory turnover ratio of 0 which shows that the management is inefficient in relation to its Inventory and working capital management.

  • Sales growth: - Genomic Valley has reported revenue growth of 3758.22657445723 % which is fair in relation to its growth and performance.

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Genomic Valley for the current financial year is 32.3762699176755 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Genomic Valley is Rs 0 and the yield is 0 %.

Last Updated on:
Brief about Genomic Valley
X